Windlas Biotech Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5f5wrj3k4x7q8gw0kh8g6f31.pdf

Key Takeaways


Revenue Growth & Composition

Komal Gupta: "If everyone is wanting to give us the credit, we did work more to deliver this kind of growth. We agree."

Margin & Cost Structure

Komal Gupta: "Exactly when the correct operational efficiency balance along with the revenue and capacity expansion hits is difficult to mention the timeline, but we see margins growing as you have been seeing consistently."

Capacity Expansion: Plant 6 & Injectables


Trade Generics: Competitive Dynamics & Distribution

Hitesh Windlass: "The goal is never to have a winner takes all. And in these complicated markets, Cipla is, even though it's been around for 40 years, but Leeford is also about the same size, which they have built in the last 15 years."

Exports & Regulatory Progress


Strategy & Capital Allocation

Hitesh Windlass: "Our strategy is that as we add a dosage form, it should cater to all 3 of our verticals. So we have to be able to use it in TGx Institution, in CDMO as well as in exports."

Guidance & Commitments

CommitmentSpecificsTimeline
Plant 6 mechanical refurbishment2-3 more quarters of work, then validationPhase-wise commercialization late FY26; full facility FY27
Revenue capacity post-Plant 6INR 1,000 crores aside from injectablesWhen Plant 6 is fully capitalized (FY27)
Injectable Phase II expansionTriggered when near peak utilization (~INR 100 crore revenue run rate)~2 quarters from trigger; only after Plant 6 is finished
Dividend payoutContinue distributing close to 20% of profitOngoing, subject to board approval
Organic CapEx for next dosage formIf no M&A materializes after injectables stabilize and Plant 6 is runningNo date (conditional on two prior milestones)

Key Metrics

MetricQ1 FY26
Revenue₹210 cr, +20% YoY
EBITDA₹27 cr, +27% YoY
PAT₹18 cr, +31% YoY
EPS₹8.4, +30% YoY
Gross margin38.3%, expanded 71 bps YoY
EBITDA margin12.6%, improved 70 bps YoY
CDMO revenue₹160 cr, +17.8% YoY
Trade Generics & Institutional revenue₹44 cr, +25.2% YoY
Exports revenue₹6 cr, +45.4% YoY
Dividend paid₹12.2 cr (₹5.8 per share) for FY25, paid in August 2025
Plant 6 CapEx plan₹40–50 cr, on track
Peak revenue potential (ex-injectables)₹1,000 cr, once Plant 6 is capitalized
Peak revenue potential (including injectables)₹1,100 cr, with possible upside from efficiency gains
DepreciationDecreased sequentially; current run rate is base for FY26 before Plant 6 capitalization